Reversible suppression of bone marrow response to erythropoietin in Plasmodium falciparum malaria

被引:107
|
作者
Kurtzhals, JAL
Rodrigues, O
Addae, M
Commey, JOO
Nkrumah, FK
Hviid, L
机构
[1] UNIV COPENHAGEN,INST MED MICROBIOL,CTR MED PARASITOL,COPENHAGEN,DENMARK
[2] RHIMA CTR,COPENHAGEN,DENMARK
[3] UNIV COPENHAGEN HOSP,DK-2100 COPENHAGEN,DENMARK
[4] KORLE BU TEACHING HOSP,DEPT CHILD HLTH,ACCRA,GHANA
关键词
malaria; Plasmodium falciparum; erythropoietin; erythropoiesis; anaemia;
D O I
10.1046/j.1365-2141.1997.82654.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To study the importance of bone marrow inhibition in the pathogenesis of malarial anaemia, haematological and parasitological parameters were followed in patients with acute malaria. Three patient categories were studied, severe malarial anaemia (SA), cerebral malaria (CM) and uncomplicated malaria (UM). Red cell distribution width (RDW) was used as a surrogate marker of release of young erythrocytes and reticulocytes. Initially RDW was low in all patients in spite of markedly increased concentrations of erythropoietin (EPO). 3 d after institution of treatment and coinciding with parasite clearance RDW increased dramatically, reaching the highest levels 1-2 weeks later. Although severe anaemia was corrected by blood transfusion during the first 3 d of treatment, the peak RDW correlated significantly with the initial EPO levels. This suggests that Plasmodium falciparum infection causes a rapidly reversible suppression of the bone marrow response to EPO. Furthermore, the inhibition of bone marrow response was a general finding irrespective of initial haemoglobin levels suggesting that the severity of anaemia depends upon the degree of peripheral erythrocyte destruction in patients with suppressed bone marrow response to EPO.
引用
收藏
页码:169 / 174
页数:6
相关论文
共 50 条
  • [41] Severe malaria due to plasmodium falciparum
    Arboleda Sanchez, J. A.
    Aguilar Urbano, V. M.
    Garcia Rodriguez, F. J.
    Mata Vazquez, M. I.
    MEDICINA INTENSIVA, 2010, 34 (08) : 574 - 574
  • [42] Combination chemotherapy for Plasmodium falciparum malaria
    Kremsner, PG
    Luty, AJF
    Graninger, W
    PARASITOLOGY TODAY, 1997, 13 (05): : 167 - 168
  • [43] Parkinsonism in a patient with Plasmodium falciparum malaria
    Gandarilla-Martinez, Nadia
    Carbayo-Viejo, Alvaro
    Sanchez-Gomez, Almudena
    Valldeoriola-Serra, Francesc
    PARKINSONISM & RELATED DISORDERS, 2020, 80 : 181 - 183
  • [44] THE ANEMIA OF PLASMODIUM-FALCIPARUM MALARIA
    WEATHERALL, DJ
    ABDALLA, S
    BRITISH MEDICAL BULLETIN, 1982, 38 (02) : 147 - 151
  • [45] MANAGEMENT OF PLASMODIUM-FALCIPARUM MALARIA
    PHILLIPS, RE
    MEDICAL JOURNAL OF AUSTRALIA, 1984, 141 (08) : 511 - 517
  • [46] Drug resistance in Plasmodium falciparum malaria
    Warhurst, DC
    INFECTION, 1999, 27 (Suppl 2) : S55 - S58
  • [47] Atovaquone/proguanil for Plasmodium falciparum malaria
    Sehdev, PS
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2002, 21 (08) : 787 - 789
  • [48] Clinical manifestations of Plasmodium falciparum malaria
    Alfandari, S
    Senneville, E
    Chidiac, C
    JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (06): : 1776 - 1777
  • [49] Cardiopulmonary complications in Plasmodium falciparum malaria
    不详
    INFECTION, 2005, 33 (03) : 186 - 186
  • [50] An Imported Case of Malaria with Plasmodium falciparum
    Ersan, Gursel
    Ulker, Temel
    Akkoclu, Gulgun
    Oguz, Filiz
    Kose, Sukran
    KAFKAS UNIVERSITESI VETERINER FAKULTESI DERGISI, 2012, 18 : A239 - A240